Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission

Current HIV Research

Volumn 4, Issue 3, 2006, Pages 329-345

  D'Cruz, Osmond J ^a,b   Uckun, Fatih M ^a,b  

^a PARKER HUGHES INSTITUTE   (United States)

^b Paradigm Pharmaceuticals   (United States)

Author keywords

Antiretroviral therapy; Combination therapy; Drug resistance; HAART; HIV AIDS; Non nucleoside inhibitors; Reverse transcriptase

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; DAPIVIRINE; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; MICROBICIDE; MIV 150; N [1 (1 ADAMANTYL)METHYL] N' [2 (THIAZOLYL)]THIOUREA; N [1 (1 FUROYLMETHYL)] N' [2 (THIAZOLYL)]THIOUREA; N [2 (1 CYCLOHEXENYL)ETHYL] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (2,5 DIMETHOXYPHENYLETHYL)] N' [(5 BROMOPYRIDYL)THIOUREA]; N [2 (4 METHYLPHENETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; N' [2 (2 THIOPHENE)ETHYL] N' [2 (5 BROMOPYRIDYL)]THIOUREA; NEVIRAPINE; PHI 236; PHI 240; PHI 241; PHI 244; PHI 253; PHI 346; PHI 347; PHI 443; PHI 445; PHI 509; PHI 511; PHI 512; PHI 513; PHI 535; PHI 536; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOUREA DERIVATIVE; TROVIRDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BINDING AFFINITY; BINDING SITE; CALCULATION; COMPLEX FORMATION; CRYSTAL STRUCTURE; DERIVATIZATION; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE MUTATION; GENITAL SYSTEM DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INFLAMMATION; LIGAND BINDING; LIPOPHILICITY; MEMBRANE PERMEABILITY; MOLECULAR MODEL; MUCOSA; NONHUMAN; POLYMERIZATION; REVIEW; SCORING SYSTEM; SEROCONVERSION; SEXUAL TRANSMISSION; SURFACE PROPERTY; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; BINDING SITES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS; THIOUREA;

EID: 33745826310     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016206777709519     Document Type: Review

References (118)

1. Abrahao-Junior O, Nascimento PG, Galembeck SE. (2001). Conformational analysis of the HIV-1 virus reverse transcriptase non-nucleoside inhibitors: TIBO and nevirapine. Journal of Computational Chemistry. 22: 1817-1829.
2. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team. (2001). Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. New England Journal of Medicine. 345: 398-407.
3. Artico M. (1996). Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Farmaco. 51: 305-331.
4. Balzarini J, Naesens L, Verbeken E, Laga M, Van Damme L, Parniak M, Van Mellaert L, Anne J, De Clercq E. (1998). Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS. 12: 1129-1138.
5. Bell FW, Cantrell AS, Hogberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM Jr, Noreen R, Oberg B, Palkowitz JA, Parrish CA, Pramo P, Sahlberg C, Ternansky RT, Vasileff RT, Vrang L, West SJ, Zhang H, Zhou XX. (1995). Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. Journal of Medicinal Chemistry. 38: 4929-4936.
6. Brodine SK, Mascola JR, Weiss PJ, Ito SI, Porter KR, Artenstein AW, Garland FC, McCutchan FE, Burke DS. (1995). Detection of diverse HIV-1 genetic subtypes in the USA. Lancet. 346: 1198-1199.
7. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, Morelli E, Novellino E. (2002). Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Current Pharmaceutical Design. 8:615-657.
8. Cantrell AS, Engelhardt P, Hogberg M, Jaskunas SR, Johansson NG, Jordan CL, Kangasmetsa J, Kinnick MD, Lind P, Morin JM Jr, Muesing MA, Noreen R, Oberg B, Pranc P, Sahlberg C, Ternansky RJ, Vasileff RT, Vrang L, West SJ, Zhang H. (1996). Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. Journal of Medicinal Chemistry. 39: 4261-4274.
9. Casado JL, Hertogs K, Ruiz L, Dronda F, Van Cauwenberge A, Arno A, Garcia-Arata I, Bloor S, Bonjoch A, Blazquez J, Clotet B, Larder B. (2000). Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS. 14: F1-7.
10. Centers for Disease Control. (2003). Fact Sheet: HIV/AIDS Among US Women: Minority and Young Women at Continuing Risk. Atlanta, GA. www.edc.gov/hiv/pubs/facts/women.htm (January 23, 2006, date last accessed).
11. Centers for Disease Control. (2005). Trends in HIV/AIDS Diagnoses - 33 states, 2001-2004. Morbidity and Mortality Weekly Report. 54: 1149-1153.
12. Chen CL, Uckun FM. (1999). Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-fluorophenethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method. Pharmaceutical Research. 16: 1226-1232.
13. Chen CL, Venkatachalam TK, Waurzyniak B, Chelstrom L, Uckun FM. (2001). In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenethyl)]-N′-[2-(5-bromophyridyl)]-thiourea (HI-236), a potent nonnucleoside inhibitor of HIV-1 reverse transcriptase. Arzneimittelforschung. 51: 574-581.
14. Clevenbergh P, Cua E, Dam E, Durant J, Schmit JC, Boulme R, Cottalorda J, Beyou A, Schapiro JM, Clavel F, Dellamonica P. (2002). Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients. HIV Clinical Trials. 3: 36-44.
15. Cohen MS. (2004). HIV and sexually transmitted diseases: lethal synergy. Topical HIV Medicine. 12: 104-107.
16. Cohen MS, Anderson DJ. (1999). Genitourinary mucosal defenses. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P, Wasserheit JN Eds, Sexually Transmitted Diseases, 3rd edition. New York, NY, USA: McGraw-Hill, pp 173-190.
17. Coombs RW, Reichelderfer PS, Landay AL. (2003). Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 17: 455-480.
18. D'Cruz OJ, Dong Y, Uckun FM. (2003). Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biochemical Biophysical Research Communications. 302: 253-264.
19. D'Cruz OJ, Erbeck D, Uckun FM. (2005). A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate. Toxicologic Pathology. 33: 465-476.
20. D'Cruz OJ, Samuel P, Uckun FM. (2004). PHI-443: a novel non-contraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biology of Reproduction. 71: 2037-2047.
21. D'Cruz OJ, Samuel P, Uckun FM. (2005). Conceival, a novel non-contraceptive vaginal vehicle for lipophilic microbicides. AAPS PharmSciTech. 6: E56-64. http://www.aapspharmscitech.org/ view.asp?art=pt060111
22. D'Cruz OJ, Uckun FM. (1999). Novel derivatives of phenethyl-5-bromopyridylthiourea and dihydroalkoxybenzyloxopyrimidine are dual-function spermicides with potent anti-human immunodeficiency virus activity. Biology of Reproduction. 60: 1419-1428.
23. D'Cruz OJ, Uckun FM. (2002). Pre-clinical safety evaluation of novel nucleoside analogue-based dual-function microbicides (WHI-05 and WHI-07). Journal of Antimicrobial Chemotherapy. 50: 793-803.
24. D'Cruz OJ, Uckun FM. (2004). Clinical development of microbicides for the prevention of HIV infection. Current Pharmaceutical Design. 10: 315-336.
25. D'Cruz OJ, Uckun FM. (2004). Preclinical overview of WHI-07, a novel nucleoside analog-based dual function microbicide. Current Medicinal Chemistry. 3: 15-29.
26. D'Cruz OJ, Uckun FM. (2004). Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Fertility & Sterility. 81 Suppl 1: 831-841.
27. D'Cruz OJ, Uckun FM. (2005). Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide. Molecular Human Reproduction. Epub, October 27. doi: 10.1093/molehr/gah236. 11: 767-777.
28. D'Cruz OJ, Uckun FM. (2006). Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. Journal of Antimicrobial Chemotherapy. Epub January 23. doi: 10.1093/jac/dki464. 57: 411-423.
29. D'Cruz OJ, Venkatachalam TK, Mao C, Qazi S, Uckun FM. (2002). Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biology of Reproduction. 67: 1959-1974.
30. D'Cruz OJ, Venkatachalam TK, Uckun FM. (2000). Novel thiourea compounds as dual-function microbicides. Biology of Reproduction. 63: 196-205.
31. D'Cruz OJ, Waurzyniak B, Uckun FM. (2002). A 13-week sub-chronic intravaginal toxicity study of the novel broad-spectrum anti-HIV and spermicidal agent, N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea (PHI-346) in mice. Toxicologic Pathology. 30: 687-695.
32. D'Cruz OJ, Yiv SH, Uckun FM. (2001). GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion. AAPS PharmSciTech. 2: E5. http://www.aapspharmscitech.org/view.asp?art=pt020205&pdf=yes
33. De Clercq E. (1992). Inhibitors targeted at the reverse transcriptase. AIDS Research and Human Retroviruses. 8: 119-134.
34. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V. (2001). Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. Journal of Medical Virology. 65: 445-448.
35. Di Fabio S, Van Roey J, Giannini G, van den Mooter G, Spada M, Binelli A, Pirillo MF, Germinario E, Belardelli F, de Bethune MP, Vella S. (2003). Inhibition of vaginal transmission of HIV-1 in huSCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS. 17: 1597-1604.
36. Ding J, Das K, Hsiou Y, Sarafianos SG, Clark AD Jr, Jacobo-Molina A, Tantillo C, Hughes SH, Arnold E. (1995). Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8Å resolution. Structure. 3: 365-379.
37. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. (1995). Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Structural Biology. 2: 303-308.
38. European Study Group on Heterosexual Transmission of HIV. (1992). Comparison of female-to-male and male-to-female transmission of HIV in 563 stable couples. British Medical Journal. 304: 809-813.
39. Fichorova RN, Tucker LD, Anderson DJ. (2001). The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. Journal of Infectious Diseases. 184: 418-428.
40. Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R. (2005). The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. Journal of Virology. 79: 11179-11186.
41. Hachiya A, Gatanaga H, Kodama E, Ikeuchi M, Matsuoka M, Harada S, Mitsuya H, Kimura S, Oka S. (2004). Novel patterns of nevirapine resistance-associated mutations of human unmunodeficiency virus type 1 in treatment-naive patients. Virology. 327: 215-224.
42. Hart CE, Lennox JL, Pratt-Palmore M, Wright TC, Schinazi RF, Evans-Strickfaden T, Bush TJ, Schnell C, Conley LJ, Clancy KA, Ellerbrock TV. (1999). Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. Journal of Infectious Diseases. 179: 871-882.
43. Hogberg M, Sahlberg C, Engelhardt P, Noreen R, Kangasmetsa J, Johansson NG, Oberg B, Vrang L, Zhang H, Sahlberg BL, Unge T, Lovgren S, Fridborg K, Backbro K. (1999). Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. Journal of Medicinal Chemistry. 42: 4150-4160.
44. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK, Stuart DI. (1996). Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. Journal of Medicinal Chemistry. 39: 1589-1600.
45. Hsiou Y, Das K, Ding J, Clark AD Jr, Kleim JP, Rosner M, Winkler I, Riess G, Hughes SH, Arnold E. (1998). Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. Journal of Molecular Biology. 284: 313-323.
46. Huang H, Chopra R, Verdine GL, Harrison SC. (1998). Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science. 282: 1669-1675.
47. Izopet J, Souyris C, Hance A, Sandres-Saune K, Alvarez M, Pasquier C, Clavel F, Puel J, Massip P. (2002). Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. Clinical Infectious Diseases. 185: 1506-1510.
48. Joint United Nations Program on HIV/AIDS (2004). Report on the Global HIV/AIDS Epidemic: December 2004. http://www.unaids.org/wad2004/ report.html (January 23, 2006, date last accessed)
49. Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F. (2004). Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrobial Agents & Chemotherapy. 48: 172-175.
50. Klebanoff SJ. (1992). Effects of the spermicidal agent nonoxynol-9 on vaginal microbial flora. Journal of Infectious Diseases. 165: 19-25.
51. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. (1992). Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256: 1783-1790.
52. Kolber MA, Campo RE, Dickinson GM. (2004). Development of anti-retroviral resistance of HIV-1 infected individuals on therapy: is it inevitable? IUBMB Life. 56: 301-307.
53. Kreiss J, Ngugi E, Holmes K, Ndinya AJ, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, Anzala A, Hoton D, Pummer F. (1992). Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual transmission of HIV in Nairobi prostitutes. Journal of the American Medical Association. 268: 477-482.
54. Larder BA. (1994). Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Journal of General Virology. 75: 951-957.
55. Liuzzi G, Chirianni A, Zaccarelli M, Zinzi D, Esposito V, Guadagnino V, Antinori A, Piazza M. (2004). Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay. In Vivo. 18: 509-512.
56. Mao C, Vig R, Venkatachalam TK, Sudbeck EA, Uckun FM. (1998). Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic Medicinal Chemistry Letters. 8: 2213-2218.
57. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. (1999). Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorganic Medicinal Chemistry Letters. 9: 1593-1598.
58. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. (1999). Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant HIV. Antiviral Chemistry & Chemotherapy. 10: 233-240.
59. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. (2000). Structure-based drug design of non-nucleoside inhibitors for wildtype and drug-resistant HIV reverse transcriptase. Biochemical Pharmacology. 60: 1251-1265.
60. Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, Calvez V. (2004). Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. Journal of Medical Virology. 72: 162-165.
61. Mayer KH, Anderson DJ. (1995). Heterosexual HIV-1 transmission. In: Infectious Agents and Disease. Lippincot-Raven, Philadelphia, PA, 4: 273-284.
62. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA, Sullivan JL. (1990). Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 250: 1411-1413.
63. Microbicide Research & Development: What's in the Pipeline? Global Campaign for Microbicides Fact Sheet #3. Washington, DC, May 2005. www.global-compaign.org (January 23, 2006, date last accessed).
64. Mitsuya H, Yarchoan R, Broder S. (1990). Molecular targets for AIDS therapy. Science. 249: 1533-1544.
65. Mujeeb SA, Altaf A. (2003). The AIDS pandemic. New England Journal of Medicine. 349: 814-815.
66. National Institute of Allergy and Infectious Diseases Fact Sheet. (2004). HIV infection in women. http://www.niaid.nih.gov/factsheets/ womenhiv.htm. (January 23, 2006, date last accessed).
67. Newman MC. Women and HIV. (2004). UCSF center for HIV information. March 2004. http://hivinsite.ucsf.edu/InSite.jsp?page=kb-03-01-12 (January 23, 2006, date last accessed).
68. Nicolosi A, Correa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A. (1994). The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology. 5: 570-575.
69. Niruthisard S, Roddy RE, Chutivongse S. (1991). The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sexually Transmitted Diseases. 18: 176-179.
70. Njai HF, Lewi PJ, Janssen CG, Garcia S, Fransen K, Kestens L, Vanham G, Janssen PA. (2005). Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells. Antiviral Therapy. 10: 255-262.
71. O'Sullivan B, Malone D. (2003). Nonoxynol-9 and sexually transmitted infections. Lancet Infectious Diseases. 3: 70.
72. Pantaleo JP, Graziosi C, Fauci AS. (1993). The immunopathogenesis of human immunodeficiency virus infection. New England Journal of Medicine. 328: 327-335.
73. Pedersen OS, Pedersen EB. (1999). Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antiviral Chemistry & Chemotherapy. 10: 285-314.
74. Poli G, Fauci A. (1992). The effect of cytokines and pharmacologic agents on chronic HIV-1 infection. AIDS Research and Human Retroviruses. 8: 191-197.
75. Quayle AJ, Xu C, Mayer KH, Anderson DJ. (1997). T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. Journal of Infectious Diseases. 176: 960-968.
76. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, Stammers D. (1995). High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Structural Biology. 2: 293-302.
77. Ren J, Esnouf RM, Hopkins AL, Warren J, Balzarini J, Stuart DI, Stammers DK. (1998). Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry. 37: 14394-14403.
78. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, Shih CK, Myers M, Griffin J. (1994). Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology. 68: 1660-1666.
79. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J. (1991). Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences of the United States of America. 88: 11241-11245.
80. Roddy RE, Cordero M, Cordero C, Fortney JA. (1993). A dosing study of nonoxynol-9 and genital irritation. International Journal of STD & AIDS. 4: 165-170.
81. Roddy RE, Zeking L, Ryan KA, Tamoufe U, Weir SS, Wong EL. (1998). A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. New England Journal of Medicine. 339: 504-510.
82. Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L, Tarpley WG. (1991). Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences of the United States of America. 88: 8806-8810.
83. Royes RA, Sena A, Gates W Jr, Cohen MS. (1997). Sexual transmission of HIV-1. New England Journal of Medicine. 336: 1072-1078.
84. Schafer W, Friebe WG, Leinert H, Mertens A, Poll T, von der Saal W, Zilch H, Nuber B, Ziegler ML. (1993). Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. Journal of Medicinal Chemistry. 36: 726-732.
85. Schinazi RF, Larder BA, Mellors JW. (1997). Mutations in retroviral genes associated with drug resistance. International Antiviral News. 5: 129-135.
86. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA. (1994). Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America. 91:3911-3915.
87. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Weber J, Kitchen VS. (1998). Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. Journal of Acquired Immune Deficiency Syndromes. 17: 327-331.
88. Sudbeck EA, Jennissen JD, Venkatachalam TK, Uckun FM. (1999). Inhibitor of HIV-1 reverse transcriptase: N′-(5-bromo-2-pyridyl)-N-[2-(2,5-dimethoxy phenyl)ethyl]thiourea. Acta Crystallography C. 55: 2122-2124.
89. Sudbeck EA, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlgren L, Uckun FM. (1998). Structure-based design of novel dihydroalkoxybenzyl oxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrobial Agents & Chemotherapy. 42: 3225-3233.
90. Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, Gross M, Fleming TR, Buchbinder S, Haggitt RC, Levine H, Kelly CW, Celum CL. (1999). Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sexually Transmitted Diseases. 26: 564-571.
91. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E. (1994). Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. Journal of Molecular Biology. 243:369-387.
92. Tirado G, Jove G, Reyes E, Sepulveda G, Yamamura Y, Singh DP, Kumar A. (2005). Differential evolution of cell-associated virus in blood and genital tract of HIV-infected females undergoing HAART. Virology. 334: 299-305.
93. Uckun FM, D'Cruz OJ. (1999). Prophylactic contraceptives for HIV/AIDS. Human Reproduction Update. 5: 506-514.
94. Uckun FM, D'Cruz OJ. (2006). Therapeutic innovations against human immunodeficiency virus. Expert Opinion on Therapeutic Patents. 16: 265-293.
95. Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK. (1999). N-[2-(1- cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1-cyclohexenyl)ethyl]-N′- [2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant HIV-1. Bioorganic Medicinal Chemistry Letters. 9: 2721-2726.
96. Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK. (2000). N′-[2- (4-methylphenyl)ethyl]- N′-[2-(5-bromopyridyl)]- thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Antiviral Chemistry & Chemotherapy. 11: 135-140.
97. Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, Venkatachalam TK. (1999). N′-[2- (2-thiophene)ethyl]- N′-[2- (5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorganic Medicinal Chemistry Letters. 9: 3411-3416.
98. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C, Karim SS, Masse B, Perriens J, Laga M. (2002). COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 360: 971-977.
99. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, Lewi P, Vanham G, Janssen P. (2004). In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrobial Agents & Chemotherapy. 48: 337-339.
100. Van Herrewege Y, Penne L, Vereecken C, Fransen K, van der Groen G, Kestens L, Balzarini J, Vanham G. (2002). Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. AIDS Research and Human Retroviruses. 18: 1091-1102.
101. Venkatachalam TK, Mao C, Uckun FM. (2001). Stereochemistry as a major determinant of the anti-HIV activity of chiral naphthyl thiourea (CNT) compounds. Antiviral Chemistry & Chemotherapy. 12: 213-221.
102. Venkatachalam TK, Mao C, Uckun FM. (2004). Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds. Bioorganic Medicinal Chemistry. 12: 4275-4284.
103. Venkatachalam TK, Mao C, Uckun FM. (2004). Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives. Biochemical Pharmacology. 67: 1933-1946.
104. Venkatachalam TK, Mao C, Uckun FM. (2004). Structural influence on the solid state intermolecular hydrogen bonding of substituted thioureas. Journal of Molecular Structure. 751: 45-58.
105. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM. (2000). Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic Medicinal Chemistry Letters. 10: 2071-2074.
106. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM. (2000). Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity. Antiviral Chemistry & Chemotherapy. 11: 329-336.
107. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM. (2000). Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic Medicinal Chemistry Letters. 10: 2071-2074.
108. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM. (2001) Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorganic Medicinal Chemistry Letters. 11: 523-528.
109. Venkatachalam TK, Sudbeck EA, Uckun FM. (2004). Structural influence on the anisotropic intermolecular hydrogen bonding in solid state of substituted thioureas: Evidence by X-ray crystal structure. Journal of Molecular Structure. 687: 45-56.
110. Venkatachalam TK, Uckun FM. (2004). Regiospecific synthesis of 5-halo-substituted thiophene pyridyl thiourea compounds as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Synthetic Communications. 34: 2451-2461.
111. Venkatachalam TK, Uckun FM. (2004). Synthesis of b-fluorophenethyl halopyridyl thiourea compounds as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Synthetic Communications. 34: 2463-2472.
112. Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. (1999). Sexual transmission of HIV: infectiousness and prevention. AIDS. 13: 155-166.
113. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, Uckun FM. (1998). Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Bioorganic Medicinal Chemistry. 6: 1789-1797.
114. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, Uckun FM. (1998). 5-Alkyl-2- [(methylthiomethyl)thio]- 6-(benzyl)- pyrimidin-4- (1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series. Bioorganic Medicinal Chemistry Letters. 8: 1461-1466.
115. Weir SS, Roddy RE, Zekeng L, Feldblum PJ. (1995). Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers. Genitourinary Medicine. 71: 78-81.
116. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen IW, Schlief WA, Sardana VV, Long WJ, Byrnes VW, Emini EA. (1995). L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy. 39: 2602-2605.
117. Zhang H, Dornadula G, Beumont M, Livornese L, Jr, Van Uitert B, Henning K, Pomerantz RJ. (1998). Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. New England Journal of Medicine. 339: 1803-1809.
118. Zussman A, Lara L, Lara HH, Bentwich Z, Borkow G. (2003). Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS. 17: 653-661.